FDA's VIP Pass for Urgent Drugs: Hearing Seeks Public Input
Published Date: 3/23/2026
Notice
Summary
The FDA is launching a pilot program called the Commissioner's National Priority Voucher (CNPV) to speed up reviews for important new drugs and treatments that tackle big U.S. health challenges. They’re inviting drug makers, experts, and the public to a hearing on June 12, 2026, to share ideas and feedback on how the program should work. This could mean faster approvals and quicker access to life-saving medicines without cutting corners.
Analyzed Economic Effects
6 provisions identified: 2 benefits, 4 costs, 0 mixed.
Ultra-fast FDA review target
The CNPV Pilot Program aims to cut FDA review times for qualifying NDAs, BLAs, and supplements from the typical 10–12 months to a target of 1–2 months. FDA also proposes a filing review target of 14–21 days after receipt of the final application component.
Priority areas that qualify
The program is limited to products that align with specified national priorities: public health crisis response; innovative breakthrough therapies; large unmet medical needs; onshoring and supply chain resilience; and affordability improvements. Only NDAs, BLAs, and manufacturing or efficacy supplements are listed as eligible application types.
Nontransferable voucher rule
CNPV vouchers are nontransferable: they cannot be sold or used for a different application, unlike some traditional priority review vouchers. The voucher grants expedited review for a single application to its recipient only.
Rapid sponsor response and meeting demands
Sponsors accepting a CNPV voucher are expected to respond rapidly to FDA information requests (typically within 24–48 hours), be available for ad hoc meetings during business hours, and facilitate inspections. Labeling negotiations are envisioned to be limited to a maximum of two rounds.
Presubmission, rolling, and submission deadlines
The program asks for presubmission meetings, rolling submissions of CMC information and proposed labeling at least 60 days before final module submission, and recommends limiting manufacturing facilities to no more than 2–3 per submission (with justification required for more). Sponsors are expected to submit a complete application within 2 years of voucher issuance and acknowledge participation or intent to redeem within 2 weeks of issuance.
Eligibility excludes most medical devices
Medical device applications are excluded from the CNPV Pilot Program, though combination products with a drug or biological product primary mode of action may be eligible. The program focuses on drug and biologic applications (NDAs and BLAs) and certain supplements.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09767 — Oscar Bobo: Final Debarment Order
Oscar Bobo is officially banned for 5 years from importing any drugs into the U.S. because he repeatedly brought in mislabeled medicines that don’t follow FDA rules. He ignored the chance to defend himself, so the ban started on May 15, 2026. This means no drug imports from him for a while, but he can apply to end the ban anytime if he meets FDA’s conditions.
2026-09543 — Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This affects drug makers and healthcare folks who keep track of side effects. They’re asking for comments by July 13, 2026, to help improve the process without adding extra costs or paperwork.
2026-09544 — Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If approved, the renewal keeps these products on the market with their modified risk status, affecting smokers and the tobacco industry starting May 13, 2026.
2026-09448 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; The Real Cost Campaign Outcomes Evaluation Study: Cohort 3
The FDA is asking for approval to collect info for the third group in its Real Cost Campaign, which teaches kids about the dangers of tobacco. This helps the FDA improve its anti-smoking messages and protect young people’s health. Comments on this info collection are open until June 12, 2026, with no new costs for participants.
2026-09368 — Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization; Guidance for Industry; Availability
The FDA is setting clear rules for certain new tobacco products like e-cigarettes and nicotine pouches that don’t have official approval yet. Companies selling these products without permission might face enforcement actions starting now, so they need to get authorized or risk penalties. This helps protect public health and keeps the market fair and safe.
2026-09335 — Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect and Identify Microorganism Nucleic Acids and Resistance Markers From Patients With Suspected Orthopedic Infection
Hey there! This update is all about a new medical device that helps doctors quickly find germs and their resistance traits in people who might have bone infections. It affects hospitals and labs by officially classifying this device, making it easier and faster to diagnose tough infections. The change kicks in soon, helping patients get the right treatment without delay—and it could save money by avoiding wrong meds!
Previous / Next Documents
Previous: 2026-05572 — Foreign-Trade Zone 27; Application for Subzone; Methods Machine Tools, Inc.; Acton and Sudbury, Massachusetts
Methods Machine Tools, Inc. wants to join Foreign-Trade Zone 27 by adding two new sites in Acton and Sudbury, Massachusetts. This move could help the company save on import taxes and speed up trade, but no production changes are planned yet. Public comments are open until May 4, 2026, so now’s the time to speak up!
Next: 2026-05575 — Announcement of Public Hearing
The National Commission on the Future of the Navy is holding a public hearing on March 25, 2026, to gather ideas from Congress and experts about the Navy’s future. This hearing will shape important decisions about fleet size, shipbuilding, and personnel, affecting how the Navy stays strong and ready. Anyone interested can attend or submit their thoughts by giving advance notice.